Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

BACKGROUND: Immune hyperactivity is an important contributing factor to the morbidity and mortality of COVID-19 infection. Nasal administration of anti-CD3 monoclonal antibody downregulates hyperactive immune responses in animal models of autoimmunity through its immunomodulatory properties. We perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreira, Thais G., Matos, Kimble T. F., De Paula, Giovana S., Santana, Thais M. M., Da Mata, Raquel G., Pansera, Fernando C., Cortina, Andre S., Spinola, Marcelle G., Baecher-Allan, Clare M., Keppeke, Gerson D., Jacob, Jules, Palejwala, Vaseem, Chen, Karen, Izzy, Saef, Healey, Brian C., Rezende, Rafael M., Dedivitis, Rogerio A., Shailubhai, Kunwar, Weiner, Howard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406802/
https://www.ncbi.nlm.nih.gov/pubmed/34475873
http://dx.doi.org/10.3389/fimmu.2021.709861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406802/
https://www.ncbi.nlm.nih.gov/pubmed/34475873
http://dx.doi.org/10.3389/fimmu.2021.709861

Ejemplares similares